Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 15, 2026, a projected date rather than a confirmed one. There are 7 upcoming events on record.
Cash runway is approximately 17.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Track EIKN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open EIKN in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 14, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| August 13, 2026 | Quarterly results filed (8-K) | Earnings | — |
| August 3, 2026 | 8-K filed: Leadership change | Corporate | — |
| June 10, 2026 | 8-K filed: Leadership change | Corporate | — |
| June 1, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| May 11, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 30, 2026 | Quarterly results filed (8-K) | Earnings | — |
| July 31, 2024 | BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab | Trial Milestone | Phase 1 |
| March 31, 2024 | BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab | Trial Milestone | Phase 1 |
| March 31, 2024 | Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Trial Milestone | Phase 1 |
| April 1, 2023 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Trial Milestone | Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.